Semax and Selank occupy an unusual position in the research-compound world: both have been approved medications in Russia for decades, with a substantial body of Russian-language clinical literature behind them, and both remain comparatively obscure in Western scientific publishing — a gap that says more about publishing patterns and regulatory history than about the underlying compounds.

Semax: Developed for Stroke Recovery

Semax was originally developed and approved in Russia for use in stroke recovery and certain cognitive conditions, based on research into ACTH-derived peptide fragments and their effects on brain-derived neurotrophic factor (BDNF) signaling. Its research profile in Western nootropics discussion has since expanded well beyond that original clinical use, into general cognitive-enhancement contexts with a considerably thinner evidence base than the original indication.

Selank: An Anxiolytic Cousin

Selank, developed by the same research institute, is structurally related to tuftsin, an immunomodulatory peptide, and was approved in Russia primarily for anxiety-related indications. Russian clinical research reports anxiolytic effects without the sedation profile typical of benzodiazepine-class medications — a distinction that, if it holds up under more scrutiny, would be pharmacologically notable, though it has not been extensively replicated in Western trial settings.

“Thirty years of domestic clinical use is real evidence. It is not the same evidence base Western regulators or researchers are used to evaluating.”

— a peptide researcher familiar with the Russian clinical literature

Why the Evidence Gap Exists

Much of the primary research on both compounds was published in Russian-language journals, with limited translation and limited uptake into the citation networks that Western researchers typically build on. That's a publishing and access barrier, not necessarily a reflection of research quality — but it does mean Western claims about either compound often rest on a narrower slice of the total available evidence than domestic Russian claims do.

What Community Discussion Tends to Skip

Both compounds get discussed online with a level of mechanistic confidence — specific claims about BDNF upregulation, specific anxiolytic pathways — that outpaces what's been independently replicated outside the original research institute. The underlying research questions are legitimate. The confidence level in casual discussion is generally ahead of where the independently-replicated evidence actually sits.